Hsbc Holdings PLC Sells 37,005 Shares of IDEXX Laboratories, Inc. $IDXX

Hsbc Holdings PLC reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 159,635 shares of the company’s stock after selling 37,005 shares during the period. Hsbc Holdings PLC’s holdings in IDEXX Laboratories were worth $108,053,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $26,000. Reflection Asset Management bought a new position in shares of IDEXX Laboratories in the 4th quarter worth $53,000. BDFS Capital LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $671,000. MidFirst Bank acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $2,960,000. Finally, Pacer Advisors Inc. increased its stake in IDEXX Laboratories by 10.0% during the 4th quarter. Pacer Advisors Inc. now owns 13,965 shares of the company’s stock valued at $9,448,000 after purchasing an additional 1,269 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Citigroup began coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $562.09 on Monday. The company has a market capitalization of $44.34 billion, a PE ratio of 41.39, a PEG ratio of 3.07 and a beta of 1.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average price is $561.66 and its 200-day moving average price is $620.14. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.